AI Summary
✦ ClarthaLyka Labs is a pharmaceutical company developing, manufacturing, and marketing formulations and active pharmaceutical ingredients in India. Formulations span dermatology, anti-infectives, pain management, gastrointestinal products, nutraceuticals, and injectable therapies. No major recent development provides a clear catalyst for revenue recovery or margin expansion. Revenue declined 7.3% year-on-year, while profit fell 225.2%, despite improving margins. ROE and debt-to-equity are unavailable, limiting assessment of returns and leverage effects. Improving margins contrast with sharply weaker earnings, suggesting operating gains have not offset declining revenue or other below-the-line pressures. The stock’s valuation cannot be judged against sector multiples because P/E is unavailable. Investor outlook remains neutral, with revenue restoration, earnings normalization, and balance-sheet disclosure as key open questions.
Valuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
3.20
Current
1.89
Overvalued
3.68
Undervalued
2.72
5Y Average
2.99
Current
2.63
Overvalued
3.44
Undervalued
2.55
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.9x Undervalued | -22% vs avg | +9.3% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +16.2% | 18.6% | 23.8x Undervalued | -45% vs avg | +24.6% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.8x Premium | +111% vs avg | +115.3% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.3x Fair | +13% vs avg | -1.7% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.3x Undervalued | -19% vs avg | +12.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.7x Fair | -13% vs avg | -14.9% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 37.5x Fair | -14% vs avg | +27.0% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | -11% vs avg | +31.2% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹42 CrJun 2026Latest net profit
₹2.10 CrJun 2026Latest EPS
₹0.58Jun 2026Net margin
10.8%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 21.24 | 26.76 | 31.42 | 26.98 | 30.10 | 41.16 | 32.92 | 30.52 | 29.18 | 32.97 | 30.73 | 28.03 | 42.31 |
| Expenses + | 18.69 | 22.82 | 25.56 | 24.76 | 26.05 | 35.82 | 27.83 | 27.22 | 25.82 | 36.12 | 28.83 | 32.52 | 37.72 |
| Operating Profit | 2.55 | 3.94 | 5.86 | 2.22 | 4.05 | 5.34 | 5.09 | 3.30 | 3.36 | -3.15 | 1.90 | -4.49 | 4.59 |
| OPM % | 12.01% | 14.72% | 18.65% | 8.23% | 13.46% | 12.97% | 15.46% | 10.81% | 11.51% | -9.55% | 6.18% | -16.02% | 10.85% |
| Other Income + | 0.43 | 0.25 | 0.52 | 0.38 | 0.62 | 0.13 | 0.87 | 0.82 | 0.77 | 1.21 | 1.37 | -22.50 | 0.42 |
| Interest | 1.33 | 1.17 | 1.26 | 1.04 | 0.65 | 0.52 | 0.62 | 0.52 | 0.85 | 0.79 | 0.82 | 0.87 | 1.01 |
| Depreciation | 3.34 | 3.46 | 2.72 | 2.77 | 1.68 | 1.68 | 1.75 | 1.42 | 2.11 | 2.07 | 2.15 | 2.04 | 2.01 |
| Profit before tax | -1.69 | -0.44 | 2.40 | -1.21 | 2.34 | 3.27 | 3.59 | 2.18 | 1.17 | -4.80 | 0.30 | -29.90 | 1.99 |
| Tax % | 2.37% | -34.09% | 43.33% | 33.06% | 25.64% | 24.16% | 24.79% | 44.04% | 30.77% | -24.38% | 0.00% | -0.43% | -5.53% |
| Net Profit + | -1.72 | -0.29 | 1.36 | -1.62 | 1.75 | 2.47 | 2.70 | 1.23 | 0.81 | -3.63 | 0.29 | -29.77 | 2.10 |
| EPS in Rs | -0.52 | -0.09 | 0.41 | -0.49 | 0.49 | 0.69 | 0.76 | 0.34 | 0.23 | -1.02 | 0.08 | -8.34 | 0.58 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).